Why do we need registries of patients on biologics drugs?
Novak, S.; Morović-Vergles, J.
Reumatizam 57(2): 151-153
2010
ISSN/ISBN: 0374-1338 PMID: 21875019 Document Number: 642344
Significant data on applied biologic drugs can be found in national registries of treated patients. The main reason of establishing registries is monitoring the efficacy and safety of biologic drugs in long-term treatment. Registries provide information on outcome of the disease, life quality, and risk-benefit ratio including society costs.
Document emailed within 1 workday
Related Documents
Codullo, V.; Iannone, F.; Sinigaglia, L.; Favalli, E.G.; Sarzi-Puttini, P.; Atzeni, F.; Ferraccioli, G.; Gremese, E.; Carletto, A.; Giollo, A.; Govoni, M.; Bergossi, F.; Galeazzi, M.; Cantarini, L.; Salaffi, F.; Di Carlo, M.; Bazzani, C.; Pellerito, R.; Sebastiani, M.; Ramonda, R.; Lapadula, G.; Caporali, R. 2017: Comparison of efficacy of first- versus second-line adalimumab in patients with rheumatoid arthritis: experience of the Italian biologics registries Clinical and Experimental Rheumatology 35(4): 660-665Turrisi, A.T. 2002: The new drugs and biologics as sensitizers in the treatment of non-small cell lung cancer I Suppli di Tumori: Official Journal of Societa Italiana di Cancerologia . 1(4): S55-S57
Nicita, C.; Buzzoni, C.; Chellini, E.; Ferretti, S.; Marinaccio, A.; Mensi, C.; Bisanti, L.; Candela, G.; Contrino, M.; Crocetti, E.; Donato, F.; Falcini, F.; Federico, M.; Ferretti, S.; Fusco, M.; Giacomin, A.; La Rosa, F.; Limina, R.; Mangone, L.; Michiara, M.; Pannozzo, F.; Ricci, P.; Serraino, D.; Tessandori, R.; Tisano, F.; Tumino, R.; Vercelli, M.; Zanetti, R.; Zappa, M.; Cavone, D.; Chellini, E.; De Zotti, R.; Di Marzio, D.; Forastiere, F.; Gennaro, V.; La Rosa, F.; Marinaccio, A.; Menegozzo, M.; Menegozzo, S.; Mensi, C.; Merletti, F.; Mirabelli, D.; Musti, M.; Riboldi, L.; Romanelli, A.; Tumino, R.; Caldarella, A.; Buzzoni, C.; Chellini, E.; Consonni, D.; Ferretti, S.; Intrieri, T.; Marinaccio, A.; Martini, A.; Mensi, C.; Nicita, C. 2014: A comparative analysis between regional mesothelioma registries and cancer registries: results of the ReNaM-AIRTUM project Epidemiologia e Prevenzione 38(3-4): 191-199
Tromp, M.; Méray, N.; Ravelli, A.C.J.; Reitsma, J.B.; Bonsel, G.J. 2005: Medical Record Linkage of Anonymous Registries without Validated Sample Linkage of the Dutch Perinatal Registries Studies in Health Technology and Informatics 116: 125-130
Morlans, M. 1984: Registries of renal patients: a new perspective Medicina Clinica 83(18): 756-758
Kahn, J.S..; Casseres, R.G..; Her, M.J..; Dumont, N.; Gottlieb, A.B..; Rosmarin, D. 2019: Treatment of Psoriasis With Biologics and Apremilast in Patients With a History of Malignancy: A Retrospective Chart Review Journal of Drugs in Dermatology: Jdd 18(4)
Morfeldt, L. 2011: National quality registries. Protect or sell out the patients' integrity? Lakartidningen 108(10): 521
Sobolewska-Włodarczyk, A.; Zielińska, A.; Siwiński, P.ł; Jędraszczyk, E.; Stec-Michalska, K.; Włodarczyk, M.; Wiśniewska-Jarosińska, M. 2017: The incidence rate of surgical interventions in patients with Crohn's disease treated with anti-tumour necrosis factor biologics Folia Medica Cracoviensia 57(2): 95-104
Kornetova, N.V. 1987: Meningeal tuberculosis in patients from the registries of tuberculosis dispensaries Problemy Tuberkuleza 10: 24-27
Wong, I.C. 1997: New antiepileptic drugs. Study suggests that under a quarter of patients will still be taking the new drugs after six years Bmj 314(7080): 603-604
Buss G 2015: Biologics in asthma: what's new? Revue Medicale Suisse 11(456-457): 20 22-4
Watanabe, A. 2016: Mycobacteriosis Associated with Administration of Biologics Kekkaku: 91(11-12): 677-684
Goff, M.T. 1971: Feline panleukopenia biologics Journal of the American Veterinary Medical Association 158(6): Suppl. 2: 907+
Giudice, G.D. 2001: Helivax Antex Biologics Current Opinion in Investigational Drugs 2(7): 896-899
Reinke, T. 2013: RA gets first oral agent to compete with biologics Managed Care 22(1): 12-13
Devauchelle-Pensec, V.ér.; Guellec, D. 2015: Focusing on the use of biologics in rheumatoid arthritis La Revue du Praticien 65(5): 687-688
Scott, F.W. 1971: Comments on feline panleukopenia biologics Journal of the American Veterinary Medical Association 158(6): Suppl. 2: 910-5
Kalden, J.R. 2001: How do the biologics fit into the current DMARD armamentarium? Journal of Rheumatology. Suppl 62: 27-35
Robson, D.S. 1970: Comments on methods for assaying canine biologics Journal of the American Veterinary Medical Association 156(12): 1786
La Salle, B. 1985: License requirements for recombinant DNA veterinary biologics in U.S.A Developments in Biological Standardization 59: 181-184